Physician profile
David E Born
NPI 1811994387
$5,003.34
in general payments reported to CMS, 2019-2025
37 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $643 · 2021: $38.43 · 2022: $800 · 2023: $1,161 · 2024: $867 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.92 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $806.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $490.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $302.93 | 2019-2025 | |
| Amarin Pharma, INC. | $300.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $254.06 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $206.97 | 2019-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $206.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $180.68 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $176.00 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $156.49 | 2019-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Exact Sciences Corporation | $130.35 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $110.55 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $90.75 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $82.28 | 2023-2025 | Gvoke Hypopen |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Born listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.